Australia’s Sigma Healthcare has withdrawn from the sale process for UK pharmacy chain and Sycamore Partners portfolio company Boots, stepping back from a potential transaction that was expected to value the business at up to $10bn, according to a report by Bloomberg.
The company confirmed on Monday that it had ended discussions and withdrawn its interest, stating that after an initial assessment the acquisition no longer aligned with its strategic priorities and capital allocation plans.
Sigma...
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.